Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Heron Therapeutics Inc HRTX

Healthcare Biotechnology
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and... see more

Recent & Breaking News (NDAQ:HRTX)

Heron Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference

PR Newswire February 18, 2020

Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises

PR Newswire January 13, 2020

Heron Therapeutics Announces Publication of the Mechanism of Action Data for HTX-011, a Dual-Acting Local Anesthetic Being Developed for Management of Postoperative Pain

PR Newswire December 16, 2019

Health Canada Grants Priority Review Status for Heron Therapeutics' New Drug Submission for HTX-011 for Management of Postoperative Pain

PR Newswire December 3, 2019

Heron Therapeutics to Present at the Evercore ISI HealthCONx Conference

PR Newswire November 26, 2019

Heron Therapeutics to Present at the Jefferies London Healthcare Conference

PR Newswire November 14, 2019

Heron Therapeutics to Present at the Stifel 2019 Healthcare Conference

PR Newswire November 13, 2019

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2019 and Highlights Recent Corporate Updates

PR Newswire November 12, 2019

Heron Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for HTX-011 for Management of Postoperative Pain

PR Newswire October 28, 2019

Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI® Label for Single-Dose Regimen for Patients Receiving Moderately Emetogenic Chemotherapy (MEC)

PR Newswire October 22, 2019

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Healthcare Services Group, Heron Therapeutics, Immunomedics, and Karyopharm and Encourages Investors to Contact the Firm

GlobeNewswire October 4, 2019

Heron Therapeutics Announces Pricing of Public Offering of Common Stock

PR Newswire October 3, 2019

Heron Therapeutics Announces Proposed Public Offering of Common Stock

PR Newswire October 3, 2019

Heron Announces Positive Topline Results from Phase 3b Clinical Study of HTX-011 in Total Knee Arthroplasty

PR Newswire October 2, 2019

Heron Therapeutics Appoints Kimberly Manhard to Board of Directors

PR Newswire October 1, 2019

Heron Therapeutics Appoints Stephen Davis to Board of Directors

PR Newswire October 1, 2019

Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Management of Postoperative Pain

PR Newswire October 1, 2019

Heron Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

PR Newswire September 25, 2019

Heron Therapeutics Announces Publication of Results from EPOCH 2, a Phase 3 Study of HTX-011 in Patients Undergoing Hernia Repair Surgery

PR Newswire August 20, 2019

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of HRTX, EGBN and CARB

Press Releases August 5, 2019